AR031122A1 - Uso de antagonistas de endotelina en la fabricacion de medicamentos utiles para el tratamiento del cancer y el dolor asociado con el mismo - Google Patents
Uso de antagonistas de endotelina en la fabricacion de medicamentos utiles para el tratamiento del cancer y el dolor asociado con el mismoInfo
- Publication number
- AR031122A1 AR031122A1 ARP010103755A ARP010103755A AR031122A1 AR 031122 A1 AR031122 A1 AR 031122A1 AR P010103755 A ARP010103755 A AR P010103755A AR P010103755 A ARP010103755 A AR P010103755A AR 031122 A1 AR031122 A1 AR 031122A1
- Authority
- AR
- Argentina
- Prior art keywords
- cancer
- manufacture
- treatment
- same
- pain associated
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 206010027452 Metastases to bone Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 206010065687 Bone loss Diseases 0.000 abstract 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000008416 bone turnover Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000002308 endothelin receptor antagonist Substances 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63338900A | 2000-08-07 | 2000-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031122A1 true AR031122A1 (es) | 2003-09-10 |
Family
ID=24539436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010103755A AR031122A1 (es) | 2000-08-07 | 2001-08-06 | Uso de antagonistas de endotelina en la fabricacion de medicamentos utiles para el tratamiento del cancer y el dolor asociado con el mismo |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1347751B1 (enExample) |
| JP (3) | JP4217068B2 (enExample) |
| KR (1) | KR20030027007A (enExample) |
| CN (1) | CN1635878A (enExample) |
| AR (1) | AR031122A1 (enExample) |
| AT (1) | ATE465728T1 (enExample) |
| AU (2) | AU2001281134B2 (enExample) |
| BG (1) | BG107577A (enExample) |
| BR (1) | BR0108865A (enExample) |
| CA (1) | CA2416879C (enExample) |
| DE (1) | DE60141979D1 (enExample) |
| HU (1) | HUP0302977A2 (enExample) |
| IL (1) | IL153769A0 (enExample) |
| MX (1) | MXPA03000984A (enExample) |
| NO (1) | NO20030593D0 (enExample) |
| NZ (1) | NZ523562A (enExample) |
| PE (1) | PE20020273A1 (enExample) |
| PL (1) | PL366160A1 (enExample) |
| SK (1) | SK1782003A3 (enExample) |
| TW (1) | TWI306760B (enExample) |
| WO (1) | WO2002011713A2 (enExample) |
| ZA (1) | ZA200300253B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0219660D0 (en) * | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
| GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| PL1765391T3 (pl) * | 2004-06-07 | 2013-08-30 | Qu Biologics Inc | Kompozycje bakteryjne do leczenia nowotworów |
| US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| CA2904447C (en) | 2007-08-22 | 2017-01-03 | Abbvie Deutschland Gmbh & Co Kg | Therapy for complications of diabetes |
| WO2011114103A1 (en) | 2010-03-18 | 2011-09-22 | Biolipox Ab | Pyrimidinones for use as medicaments |
| ES2645509T3 (es) | 2010-07-26 | 2017-12-05 | Qu Biologics Inc | Composiciones antiinflamatorias inmunogénicas |
| CN102485238A (zh) * | 2010-12-06 | 2012-06-06 | 陈炯华 | 芎芷镇痛方 |
| CA3254723A1 (en) | 2014-05-02 | 2025-04-15 | Qu Biologics Inc | ANTIMICROBIAL IMMUNOMODULATION |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6063911A (en) * | 1993-12-01 | 2000-05-16 | Marine Polymer Technologies, Inc. | Methods and compositions for treatment of cell proliferative disorders |
| NZ330818A (en) * | 1996-02-13 | 2000-05-26 | Abbott Lab | Benzo-1, 3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists |
| TR200101234T2 (tr) | 1997-08-04 | 2002-06-21 | Abbott Laboratories | Endotelin antagonistleri. |
| AU4382499A (en) * | 1998-12-11 | 2000-07-03 | Mactapes Limited | Curtain heading tape manufacture |
| US6545048B1 (en) * | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
-
2001
- 2001-07-24 TW TW090118053A patent/TWI306760B/zh active
- 2001-08-06 CA CA002416879A patent/CA2416879C/en not_active Expired - Fee Related
- 2001-08-06 WO PCT/US2001/024716 patent/WO2002011713A2/en not_active Ceased
- 2001-08-06 IL IL15376901A patent/IL153769A0/xx unknown
- 2001-08-06 SK SK178-2003A patent/SK1782003A3/sk unknown
- 2001-08-06 AT AT01959595T patent/ATE465728T1/de not_active IP Right Cessation
- 2001-08-06 CN CNA018169929A patent/CN1635878A/zh active Pending
- 2001-08-06 AR ARP010103755A patent/AR031122A1/es not_active Application Discontinuation
- 2001-08-06 AU AU2001281134A patent/AU2001281134B2/en not_active Ceased
- 2001-08-06 AU AU8113401A patent/AU8113401A/xx active Pending
- 2001-08-06 DE DE60141979T patent/DE60141979D1/de not_active Expired - Lifetime
- 2001-08-06 EP EP01959595A patent/EP1347751B1/en not_active Expired - Lifetime
- 2001-08-06 PE PE2001000782A patent/PE20020273A1/es not_active Application Discontinuation
- 2001-08-06 PL PL01366160A patent/PL366160A1/xx unknown
- 2001-08-06 HU HU0302977A patent/HUP0302977A2/hu unknown
- 2001-08-06 JP JP2002517050A patent/JP4217068B2/ja not_active Expired - Fee Related
- 2001-08-06 BR BR0108865-3A patent/BR0108865A/pt not_active Application Discontinuation
- 2001-08-06 NZ NZ523562A patent/NZ523562A/en unknown
- 2001-08-06 KR KR10-2003-7001735A patent/KR20030027007A/ko not_active Ceased
- 2001-08-06 MX MXPA03000984A patent/MXPA03000984A/es active IP Right Grant
-
2003
- 2003-01-09 ZA ZA200300253A patent/ZA200300253B/en unknown
- 2003-02-06 NO NO20030593A patent/NO20030593D0/no not_active Application Discontinuation
- 2003-02-21 BG BG107577A patent/BG107577A/bg unknown
-
2006
- 2006-11-08 JP JP2006302713A patent/JP2007084564A/ja active Pending
- 2006-11-08 JP JP2006302712A patent/JP2007063288A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI306760B (en) | 2009-03-01 |
| CA2416879C (en) | 2006-11-07 |
| CA2416879A1 (en) | 2002-02-14 |
| JP2007084564A (ja) | 2007-04-05 |
| WO2002011713A2 (en) | 2002-02-14 |
| AU8113401A (en) | 2002-02-18 |
| DE60141979D1 (de) | 2010-06-10 |
| MXPA03000984A (es) | 2003-09-05 |
| PE20020273A1 (es) | 2002-04-16 |
| EP1347751B1 (en) | 2010-04-28 |
| IL153769A0 (en) | 2003-07-06 |
| BR0108865A (pt) | 2005-04-19 |
| NO20030593L (no) | 2003-02-06 |
| JP2004520266A (ja) | 2004-07-08 |
| HUP0302977A2 (hu) | 2003-12-29 |
| NZ523562A (en) | 2006-10-27 |
| NO20030593D0 (no) | 2003-02-06 |
| BG107577A (bg) | 2003-10-31 |
| EP1347751A2 (en) | 2003-10-01 |
| WO2002011713A3 (en) | 2003-07-17 |
| SK1782003A3 (en) | 2003-08-05 |
| ZA200300253B (en) | 2004-11-17 |
| ATE465728T1 (de) | 2010-05-15 |
| CN1635878A (zh) | 2005-07-06 |
| AU2001281134B2 (en) | 2005-06-09 |
| JP4217068B2 (ja) | 2009-01-28 |
| JP2007063288A (ja) | 2007-03-15 |
| KR20030027007A (ko) | 2003-04-03 |
| PL366160A1 (en) | 2005-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR033555A1 (es) | Producto para el tratamiento del carcinoma de receptor de estrogeno positivo, y uso de dicho producto para preparar medicamentos | |
| ATE282428T1 (de) | Pharmazeutische dosierungsform von amorphem nilfenavir mesylat | |
| AR029763A1 (es) | Uso de una combinacion de una nsaid y un inhibidor de quinasa egfr para la manufactura de un medicamento para el tratamiento o inhibicion de polipos colonicos y cancer colorectal, composicion farmaceutica y medicamento | |
| CO5011096A1 (es) | Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs | |
| CY1112361T1 (el) | Σκευασματα για αντικαρκινικη θεραπεια που περιεχουν εκτεϊνασκιδινη 743 | |
| BG66093B1 (bg) | Състави с контролирано освобождаване, съдържащи нимесулид | |
| CY1105070T1 (el) | Μεθοδος και συνθεσεις που χρησιμοποιουν κιναζολινονες | |
| ATE431738T1 (de) | Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist | |
| NO993520L (no) | Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon | |
| BR0110028A (pt) | Uso de antagonistas-ngf para a prevenção ou tratamento de dor visceral crÈnica | |
| NO20053224D0 (no) | Patient controlled drug administration device. | |
| ATE333896T1 (de) | Vaskularisierungsinhibitoren | |
| SE0002754D0 (sv) | New pharmaceutical combination formulation and method of treatment with the combination | |
| EE200300193A (et) | Asendatud bensimidasoolid, nende kasutamine ja ravim | |
| AR034517A1 (es) | Formulacion farmaceutica | |
| TR200502508T2 (tr) | IL-18 İnhibitörlerinin kullanımı. | |
| AR031122A1 (es) | Uso de antagonistas de endotelina en la fabricacion de medicamentos utiles para el tratamiento del cancer y el dolor asociado con el mismo | |
| ITRM20010226A1 (it) | Dispositivo impiantabile di altezza ridotta per la somministrazione di preparati medicinali. | |
| ZA200208761B (en) | Pharmaceutical form of administration for peptides, methods for its production and use. | |
| UY28007A1 (es) | Tratamiento terapeutico | |
| TR199902980T2 (xx) | Diabetin tedavisi i�in leptin antagonistlerinin kullan�m�. | |
| DE60102590D1 (de) | Darreichungsformen zur behandlung von oralen mykosen | |
| AR032422A1 (es) | Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca | |
| AR041595A1 (es) | Tratamiento terapeutico | |
| CY1107062T1 (el) | ΧΡΗΣΗ ΔΡΑΣΤΙΚΩΝ ΟΥΣΙΩΝ ΜΕ ΔΡΑΣΗ ΑΓΩΝΙΣΤΗ μ-ΥΠΟΔΟΧΕΑ ΟΠΙΟΕΙΔΩΝ ΚΑΙ ΔΡΑΣΗ ΑΝΤΑΓΩΝΙΣΤΗ ΥΠΟΔΟΧΕΑ ΟΠΙΟΕΙΔΩΝ ΩΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΜΕΣΑ ΣΥΝΔΥΑΣΜΟΥ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΟΥ ΚΑΡΚΙΝΟΥ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |